Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Background: Clozapine remains the only evidence-based antipsychotic for treatment-resistant schizophrenia (TRS). The ability to predict which patients with their first onset of schizophrenia would subsequently meet criteria for treatment resistance (TR) could help to diminish the severe functional disability which may ensue if TR is not recognized and correctly treated. Method: This is a 5-year longitudinal assessment of clinical outcomes in a cohort of 246 first-episode schizophrenia spectrum patients recruited as part of the NIHR Genetics and Psychosis (GAP) study conducted in South London from 2005 to 2010. We examined the relationship between baseline demographic and clinical measures and the emergence of TR. TR status was determined from a review of electronic case records. We assessed for associations with early-, and late-onset TR, and non-TR, and differences between those TR patients treated with clozapine and those who were not. Results: Seventy per cent ( n = 56) of TR patients, and 23% of the total study population ( n = 246) were treatment resistant from illness onset. Those who met criteria for TR during the first 5 years of illness were more likely to have an early age of first contact for psychosis (<20 years) [odds ratio (OR) 2.49, 95% confidence interval (CI) 1.25–4.94] compared to those with non-TR. The relationship between an early age of first contact (<20 years) and TR was significant in patients of Black ethnicity (OR 3.71, 95% CI 1.44–9.56); and patients of male gender (OR 3.13 95% CI 1.35–7.23). Conclusions: For the majority of the TR group, antipsychotic TR is present from illness onset, necessitating increased consideration for the earlier use of clozapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prevalence estimates of TRS, TRD, and treatment resistant OCD vary from 20-60% of the population with the condition. 26, 35–40”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · cited 1×
“The degree of psychopathology at first presentation to mental health services was measured on the Positive and Negative Syndrome Scale (PANSS; Kay et al. 1987).”
MethodA solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711 · cited 1×
“Penalized logistic regression (PLR) was used to analyse the relationship between the predictors for TR (Heinze & Schemper, 2002).”
MethodRemission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,343 · cited 1×
“…for TR. Similar to earlier work conducted in the same geographical region (Morgan et al. 2014; Revier et al. 2015), and in keeping with work from Andreasen et al. (2005), using information extracted from clinical records, remission was defined as the absence of overt psychotic symptoms,…”
ResultMcGuffin, P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320088015 · Cited by 1,483 · cited 2×
“The OPCRIT system consists of a 90-item checklist and uses computerized diagnostic algorithms based on published criteria to provide a diagnostic category for each subject employing a number of classification systems (McGuffin et al. 1991).”
MethodNatural Course of Schizophrenic Disorders: A 15-Year Followup of a Dutch Incidence Cohort
Wiersma, D., Nienhuis, F. J., Slooff, C. J., & Giel, R. (1998) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033315 · Cited by 649 · cited 3×
“This finding mirrors the rate of 20% who displayed ‘chronicity’ from illness outset in a FEP population (Wiersma et al. 1998), although is higher than a previous finding of 10% of FEP cases found to have shown no response to antipsychotics at the end of the first year of treatment (Robinson et al.…”
BackgroundResultHigh-potency cannabis and the risk of psychosis
Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T. R., Handley, R., Luzi, S., Russo, M., Paparelli, A., et al. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.064220 · Cited by 567 · cited 1×
“A detailed assessment of lifetime patterns of cannabis use and alcohol intake was collated employing the Cannabis Experience Questionnaire modified version (Di Forti et al. 2009).”
MethodSelf-citationTreatment-Resistant Schizophrenia - The Role of Clozapine
Meltzer, H. Y. (1997) · Current Medical Research and Opinion · doi:10.1185/03007999709113338 · Cited by 491 · cited 3×
“Although, a few potential risk factors for TR, such as poor premorbid functioning, living in less urban areas, co-morbid personality disorder, longer duration of untreated psychosis (DUP), greater severity of negative symptoms, and a younger age of illness onset have been suggested (Vanelle et al. 1994; Meltzer, 1997;…”
BackgroundDi Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., Marconi, A., La Cascia, C., Reis Marques, T., Pariante, C., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt181 · Cited by 470 · cited 1×
“Further details of the study are available in Di Forti et al. (2014).”
BackgroundSelf-citationPredictors of Treatment Response From a First Episode of Schizophrenia or Schizoaffective Disorder
Robinson, D. G., Woerner, M. G., Alvir, J. M. J., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., Bilder, R., Goldman, R., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.544 · Cited by 466 · cited 2×
“1998), although is higher than a previous finding of 10% of FEP cases found to have shown no response to antipsychotics at the end of the first year of treatment (Robinson et al. 1999).”
ResultWechsler Adult Intelligence Scale
Szczepkowski, K. V., & Demakis, G. J. (2017) · Encyclopedia of Personality and Individual Differences · doi:10.1007/978-3-319-28099-8_1034-1 · Cited by 440
Research works printed but not linked: 2
- 1994, Schedules for Clinical Assessment in Neuropsychiatry: Version 2: Manual
- 1992, The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Self-citationImproving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Self-citationKaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Self-citationPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
Self-citation
Metadata
- Authors
- Lally, J., Ajnakina, O., Di Forti, M., Trotta, A., Demjaha, A., Kolliakou, A., Mondelli, V., Reis Marques, T., Pariante, C., Dazzan, P., Shergil, S. S., Howes, O. D., David, A. S., MacCabe, J. H., Gaughran, F., & Murray, R. M.
- Affiliations
- National Health Service (GB)
- King's College London (GB)
- Corresponding author
- Lally, J.
- ORCID
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2016-09-08
- Volume
- 46
- Issue
- 15
- Pages
- 3231-3240
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2517254183
- Cited by
- 298
- References
- 51
- Citations by year
- 2026: 34 · 2025: 26 · 2024: 31 · 2023: 29 · 2022: 34 · 2021: 36 · 2020: 32 · 2019: 33 · 2018: 29 · 2017: 12 · 2016: 2
- FWCI
- 22.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Psychological Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc-sa)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Sunovion
- Psychiatry Research Trust
- National Institute for Health and Care Research (CL-2008-17-005, Grant Reference Number RP-PG-0606-1049, NF-SI-0512-10110, 0606-1049, RP-PG-0606-1049, PG-0606-1049)
- Academy of Medical Sciences (AMS-SGCL5-Mondelli)
- King's College London
- Servier
- H. Lundbeck A/S
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- Medical Research Council (MR/L003988/1, MR/K004867/1, MR/L011794/1, MR/K013807/1)
- Cilag
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Keywords
- treatment-resistant schizophrenia, first-episode psychosis, schizophrenia spectrum disorders, clozapine, early-onset psychosis, clinical predictors, Black ethnicity, sex differences, antipsychotic treatment resistance, functional disability
- MeSH terms
- Adult, Age Factors, Clozapine, Drug Resistance, Female, Humans, London, Longitudinal Studies, Male, Psychotic Disorders, Risk Factors, Schizophrenia, Schizophrenic Psychology, Sex Factors, Antipsychotic Agents, Odds Ratio, Black People, White People, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. https://app.cochat.ai/papers/10.1017/s0033291716002014
- The paper
- Lally, J., Ajnakina, O., Di Forti, M., Trotta, A., Demjaha, A., Kolliakou, A., Mondelli, V., Reis Marques, T., Pariante, C., Dazzan, P., Shergil, S. S., Howes, O. D., David, A. S., MacCabe, J. H., Gaughran, F., & Murray, R. M. (2016). Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine. https://doi.org/10.1017/s0033291716002014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.